



Synlogic to Present at the Leerink Partners 7th Annual Global Healthcare Conference

February 8, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2018-- Synlogic([Nasdaq:SYBX](https://www.nasdaq.com/symbol/sybx)) announced today that its chief medical officer, Aoife Brennan, M.B., B.Ch., and chief financial officer, Todd Shegog will present a corporate update at the Leerink Partners 7th Annual Global Healthcare Conference at 3:00 p.m. ET, on Thursday, February 15, 2018, in New York City.

A live webcast of the presentation can be accessed under "Presentations" in the Investors & Media section of the Company's website at www.synlogictx.com. An archived webcast recording will be available on the Synlogic website for approximately 30 days after the event.

About Synlogic

Synlogic is pioneering the development of a novel class of living treatments, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic's initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20180208006381/en/>

Source: Synlogic

Synlogic

MEDIA CONTACT:

Courtney Heath, 617-872-2462

courtney@scientpr.com

or

INVESTOR CONTACT:

Elizabeth Wolffe, Ph.D., 617-207-5509

liz@synlogictx.com